Restarting Apixaban After Surgery: Dose Recommendations
For most patients, apixaban should be restarted at the SAME dose as before surgery, but the timing depends critically on the bleeding risk of the procedure—not the dose itself. The key distinction is between low and high bleeding risk surgery, which determines when to restart, not whether to modify the dose.
Timing-Based Approach to Restarting Apixaban
Low Bleeding Risk Surgery
- Resume apixaban 24 hours after surgery at the full pre-operative dose (typically 5 mg twice daily for atrial fibrillation) 1, 2
- This applies to procedures where bleeding is easily controllable and hemostasis is adequate
High Bleeding Risk Surgery
The evidence supports a more cautious approach with two options:
Standard approach: Resume full-dose apixaban (5 mg twice daily) 48-72 hours after surgery once adequate hemostasis is established 1, 2
High thrombotic risk patients: Consider using a reduced dose initially (apixaban 2.5 mg twice daily) for the first 2-3 days post-operatively, then increase to the full therapeutic dose 1
Critical Considerations
The FDA label explicitly states: "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established" 3. This emphasizes that hemostasis, not a fixed time interval, should guide resumption.
Why Dose Reduction May Be Considered
The guideline rationale for potential dose reduction in high-risk scenarios stems from apixaban's rapid onset of action (peak levels at 1-3 hours), which is similar to therapeutic-dose enoxaparin 1. Resuming full-dose apixaban immediately carries similar bleeding risk to resuming treatment-dose LMWH bridging, which is why cautious timing or temporary dose reduction is suggested for major surgery.
Bridging Is NOT Recommended
Do not bridge with enoxaparin during the 24-48 hours after stopping apixaban and before surgery 3. Similarly, bridging is not generally required when restarting apixaban post-operatively 2, 4.
Practical Algorithm
Step 1: Classify surgical bleeding risk
- Low risk: dental, dermatologic, cataract, minor procedures
- High risk: major abdominal, orthopedic, neurosurgery, cardiac surgery
Step 2: Assess patient thrombotic risk
- High risk: mechanical heart valve, recent VTE (<3 months), atrial fibrillation with prior stroke
Step 3: Apply restart strategy
| Surgery Type | Thrombotic Risk | Restart Timing | Dose |
|---|---|---|---|
| Low bleeding risk | Any | 24 hours post-op | Full pre-op dose |
| High bleeding risk | Standard | 48-72 hours post-op | Full pre-op dose |
| High bleeding risk | High thrombotic risk | 24-48 hours post-op | Consider 2.5 mg BID × 2-3 days, then full dose |
Common Pitfalls to Avoid
Don't automatically reduce the dose for all patients—most can safely resume their full pre-operative dose with appropriate timing 2
Don't restart too early after high-risk surgery—the 2018 EHRA guidelines emphasize waiting 48-72 hours for high bleeding risk procedures 2
Don't use bridging anticoagulation routinely—this increases bleeding risk without reducing thrombotic events 4, 5
Ensure adequate hemostasis first—this takes precedence over any fixed time interval 3
The 2022 CHEST guidelines support waiting at least 24 hours before resuming any anticoagulation after surgery, with longer delays (48-72 hours) for high-bleeding-risk procedures 4. The dose itself typically remains unchanged; it's the timing that requires careful consideration based on surgical bleeding risk and adequacy of hemostasis.